SemaThera Inc.
  • About Us
    • About Us
    • Management
    • Board of Directors
  • Technology
    • Technology
    • Scientific Publications
  • Investors
  • Partners
  • News
  • Contact Us
    • Careers
Select Page

Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience

Press Release August 12, 2018 – Chiome Bioscience Inc. (hereinafter, “Chiome”) announced today that it has executed a Collaborative Development License and Exclusive Option Agreement (hereinafter, “Agreement”) with SemaThera Inc. (Home office: Montreal, Canada;...

Mike Sapieha a reçu le prix du jeune chercheur André-Dupont

Mike Sapieha Wins Prestigious Cogan Award

Mike Sapieha received a 2017 CAN Young Investigator Award

Mike Sapieha a reçu le prix de soutien Joe-Doupe à un chercheur débutant 2017

Recent News

  • SemaThera Board Names Garth Cumberlidge as President & CEO November 1, 2018
  • Execution of the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody developed by Chiome Bioscience August 12, 2018
  • SemaThera Announces a $2MUS Financing and a Licensing Deal for China and Japan March 21, 2018
  • AmorChem spins out its SEMA 3A technology into SemaThera, with 1m$ seed investment January 11, 2017

1 Westmount Square
Suite 800
Montreal, Quebec
H3Z 2P9

Business Development: bd@semathera.com

Human Resources: careers@semathera.com

General Inquiries: info@semathera.com

 

 

© Copyright 2018 SemaThera Inc.



© Copyright 2018 SemaThera Inc.